We are live on ! Find out more

Haemonetics

HAE

Market cap $4.69B

103.16 USD

+0.32

0.31%

At close Updated Sep 9, 4:00 PM EDT

Pre-market

After hours

103.16

0.00

0%

1 day

0.31%

5 days

0.9%

1 month

19.11%

3 months

31.06%

6 months

60.61%

Year to date

28.98%

1 year

90.19%

5 years

57.11%

10 years

185.13%

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Employees: 3,009

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.1%

Neutral 42.1%

Negative 15.8%

Zacks Investment Research

GEHC vs. HAE: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?

GEHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Zacks Investment Research

Here's Why Haemonetics (HAE) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Haemonetics (HAE) is a Strong Momentum Stock

Zacks Investment Research

Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Zacks Investment Research

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

Haemonetics Q1 Earnings Call Highlights

Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.

Haemonetics Q1 Earnings Call Highlights

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Zacks Investment Research

Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago.

Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™